ClinicalTrials.gg
RecruitingNCT07501026neoSFRT-SARCUpdated Mar 30, 2026

Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC)

A Phase 2 interventional study of SFRT in Sarcoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Sarcoma with a site in China — 68 open to participants now, 74 under way, 1 of them phase 3. Sarcoma · China.

Planned enrollment
95th of 122
22 · median 45
Started
2026
with 15 others
Phase 2
67 of 133
32 open now
Primary completion
2028-03
later than 61 of 73 live
Registered
120th of 133
by date
Lead sponsor
7 of 133
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 133 studies in Sarcoma with a site in China, this one is the 95th largest by planned enrollment of the 122 interventional ones that give a count, is one of 16 that started in 2026, is one of 67 in phase 2, reaches primary completion later than 61 of the 73 other live ones, and was the 120th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

68 of the 133 studies in Sarcoma with a site in China are open now. Recruiting first, the newest first:

62 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sarcoma with a site in China, or all of them as a file.
02

Study summary

The goal of this prospective, single-arm, phase II trial is to evaluate whether a preoperative regimen combining spatially fractionated radiation therapy (SFRT) with subsequent surgery can improve outcomes in patients with large (≥5 cm) limb/trunk soft tissue sarcoma (STS). Currently, there is a lack of standardized SFRT-based protocols for operable or borderline-resectable large STS, and optimal dose-fractionation schedules, timing to surgery, differential efficacy by resectability status, and the induced systemic immune response remain undefined. Patients will receive 5 fractions of SFRT to the primary tumor, followed by definitive surgery. The main questions are:

  • Can this SFRT-first approach increase the 1-year disease-free survival (DFS) compared with historical controls?
  • What are the pathologic complete response (pCR) rate, overall survival (OS), and treatment-related safety profile?
  • What immune mechanisms are engaged by SFRT, as reflected by dynamic changes in peripheral immune cell subsets and cytokines? Participants will undergo SFRT, then surgery, with serial blood sampling for immune monitoring.
Read the detailed description

For localized STS, surgery combined with radiotherapy is the standard of care. Preoperative radiotherapy can reduce tumor volume, facilitate resection, and lower recurrence risk. However, two major challenges remain: (1) radioresistance-STS is generally radioresistant, especially in bulky tumors; pivotal studies (e.g., RTOG 0630) report pathologic complete response (pCR) rates below 20% with conventional fractionation; (2) limited local control in unresectable cases-historical data show 5-year local control below 10% for tumors >10 cm treated with definitive radiotherapy alone.

Spatially fractionated radiation therapy (SFRT) delivers high-dose peaks within the tumor while maintaining lower-dose valleys, creating a non-uniform dose distribution that may enhance tumor kill, potentially trigger systemic antitumor immunity, and spare adjacent normal tissues. Recent retrospective data from Mayo Clinic (2024) demonstrated that in advanced, unresectable sarcomas, SFRT followed by conventional external-beam radiotherapy achieved 1-year local control of 82% and symptom relief in 60%, with acceptable toxicity. These promising results support prospective evaluation of SFRT in the preoperative setting for operable or borderline-resectable large STS.

Eligible patients will receive SFRT to the primary tumor in 5 fractions, followed by definitive surgery. The primary endpoint is 1-year disease-free survival (DFS). Secondary endpoints include pCR rate, overall survival (OS), and safety assessed by CTCAE v5.0. Exploratory objectives involve longitudinal monitoring of peripheral blood immune cell subsets (e.g., CD8⁺, CD4⁺, Treg cells) and cytokines (e.g., IFN-γ, TNF-α) to characterize SFRT-induced systemic immune modulation and identify potential biomarkers of response.

03

Conditions studied

  • Sarcoma

Browse trials for

Keywords

  • Spatially Fractionated Radiation Therapy (SFRT)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed soft tissue sarcoma of the extremity or trunk, with tumor size ≥5 cm in greatest dimension (by imaging or clinical examination).
  • Disease classified as operable or borderline-resectable as determined by the multidisciplinary tumor board.
  • Age ≥18 years at the time of consent.
  • (ECOG) performance status 0-2.
  • Adequate organ function as defined by:

≥1.5 × 10⁹/L; count ≥100 × 10⁹/L; ≥9.0 g/dL; Total ≤1.5 × (ULN) (or ≤3 × ULN in patients with Gilbert's syndrome); /ALT ≤2.5 × ULN; ≥50 mL/min (by Cockcroft-Gault or measured);

  • Women of must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use effective during the study treatment period and for at least 3 months after the last study procedure. Men with partners of childbearing potential must agree to use effective contraception during the same period.
  • Willing and able to provide written and comply with all study procedures, including scheduled follow-up visits and blood sample collections.

Exclusion criteria

Exclusion Criteria:

  • Prior radiotherapy to the same anatomical site that would result in overlap of radiation fields.
  • Distant at the time of enrollment (M1 disease).
  • Pregnancy or breastfeeding.
  • Active second requiring systemic therapy within the past 3 years, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ.
  • Severe, active comorbidities including but not limited to:

Uncontrolled infection requiring intravenous antibiotics; Decompensated heart failure ( Class III or IV); Myocardial infarction or unstable angina within 6 months; Severe or other conditions that would preclude safe radiotherapy or surgery.

  • Known to radiation therapy procedures or inability to undergo required imaging (e.g., MRI contrast allergy not manageable with premedication).
  • Concurrent participation in another interventional clinical trial with an agent within 30 days prior to enrollment.
  • Any condition that, in the opinion of the investigator, would compromise patient safety, interfere with study compliance, or preclude successful completion of the study procedures.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Preoperative SFRT

    SFRT Administration: All patients will first receive preoperative SFRT. Regimen: Total dose PTV 66.7 (lattice) / 20 Gy, delivered in 5 fractions (the fractionation pattern will be individually optimized based on tumor location and adjacent organs to ensure that doses to critical structures remain within safe limits).

    Radiation: SFRT

Interventions

  • RadiationSFRT

    1. Preoperative SFRT: The prescribed dose is 20 Gy in 5 fractions, with lattice dose of 66.7Gy in 5 fractions. 2. Surgery: Approximately one week after completion of SFRT, tumor resectability is reassessed. Patients who achieve sufficient tumor response undergo definitive surgical resection. Those who remain unsuitable for surgery after SFRT will receive alternative treatment per standard of care. 3. Translational immune monitoring: Peripheral blood samples are collected at baseline, one week post-SFRT, and at 1, 3, 6, and 12 months post-treatment for exploratory analysis of immune cell subsets (e.g., CD8⁺ T cells) and cytokine profiles (e.g., IFN-γ, TNF-α), aimed at characterizing SFRT-induced systemic immune modulation.

06

What researchers measure

Primary outcomes

  1. 1-year Disease-Free Survival (DFS)

    DFS defined as the time from enrollment to the first occurrence of local recurrence, regional recurrence, distant metastasis, or death from any cause, whichever occurs first. Patients who are alive and disease-free at 1 year are censored at their last disease assessment.

    Time frame: 1 year post-treatment

Secondary outcomes

  1. Pathologic Complete Response (pCR) Rate

    Proportion of patients with no viable residual tumor cells in the resected primary tumor specimen and regional lymph nodes (if sampled) following preoperative SFRT and surgery, assessed by central pathology review.

    Time frame: At the time of surgery (approximately 1 week after SFRT)

  2. Overall Survival (OS)

    Time from enrollment to death from any cause. Patients alive at the last follow-up are censored.

    Time frame: Up to 3 years (duration of study follow-up)

  3. Safety and Tolerability

    Incidence, severity, and attribution of adverse events (AEs) and serious adverse events (SAEs) graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Events include radiotherapy-related skin reactions, surgical complications, and systemic toxicities.

    Time frame: From SFRT initiation through 30 days after surgery (or longer for serious events)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 198 non-industry phase 2 interventional studies under Sarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 91. This study's planned 24 months is below that.

Counting every sponsor, half of 227 studies reached it within 66 months; a quarter within 43 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Mar 16, 2028
CompletionEst.
Mar 16, 2029
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07501026
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Mar 16, 2026
Primary completion
Mar 16, 2028 (estimated)
Completion
Mar 16, 2029 (estimated)
Last update
Mar 30, 2026

Study contacts

Ting Zhang, phD.
Contact
zezht@zju.edu.cn
+86-571-87783521

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion